课题基金 / 基金详情

Gene Therapy for Congenital Adrenal Hyperplasia through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2

Gene Therapy for Congenital Adrenal Hyperplasia through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2
通过使用编码人 CYP21A2 的腺相关病毒 (AAV) 血清型 5 重组载体进行先天性肾上腺增生症的基因治疗
批准号：
10691784
负责人：
Deborah Merke
金额：
$0.0万
依托单位：
CLINICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10691784
关键词：
21-hydroxylase deficiencyAdenovirus VectorAdrenal GlandsAdultAgeAnimalsBiodistributionCYP21A2 geneCardiovascular DiseasesCessation of lifeClinical TrialsCongenital adrenal hyperplasiaDependovirusDiagnosisDoseHumanIncidenceInjectionsLeadLifeLongevityMendelian disorderMetabolic DiseasesMonitorMusParticipantPatientsPhasePhenotypeQuality of lifeRecombinantsResearch DesignRiskSafetySerotypingShockSteroid 21-MonooxygenaseSteroid biosynthesisTimeWeight Gainadeno-associated viral vectorbaseclinical developmentdesigneffective therapyefficacy evaluationenzyme activityexpression vectorfirst-in-humangene therapyhuman studyintravenous injectionmortalitynonhuman primateopen labelpre-clinicalprogramssafety assessmentsexstandard of carevectorvector genome

项目摘要

项目成果

Deborah Merke的其他基金

相似基金

相关文献

中文摘要
翻译
21-羟化酶缺乏引起的先天性肾上腺增生是一种单基因疾病，可通过遗传干预。有希望的临床前项目已经导致了第一次人体临床试验。这是一项1/2期、开放标签、剂量递增的研究，旨在评估基于AAV5的基因治疗的安全性、耐受性和有效性，治疗25名被诊断为21-羟化酶缺乏症的典型先天性肾上腺增生的成年患者。所有接受基因治疗的参与者都将被密切监测一年，并至少再随访四年以观察其安全性和有效性。
英文摘要
As a monogenic disease, congenital adrenal hyperplasia due to 21-hydroxylase deficiency is amenable to genetic interventions. Promising pre-clinical programs have led to a first-in-human clinical trial. This is a Phase 1/2, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of an AAV5 based gene therapy administered to up to 25 adult participants diagnosed with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. All participants who receive gene therapy will be closely monitored for one year and followed for a minimum of an additional four years for safety and efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modified-release Hydrocortisone Therapy as a Treatment for CAH
Study of a corticotropin releasing factor-1 receptor antagonist for the treatment of congenital adrenal hyperplasia
Novel treatment approaches: sex steroid blockade in children
  • 批准号：
    10916862
  • 项目类别：
  • 资助金额：
    $0.0万
  • 财政年份：
    --
  • 负责人：
    Deborah Merke
  • 依托单位：
    CLINICAL CENTER
Phase 2 Multi-center Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
  • 批准号：
    10252568
  • 项目类别：
  • 资助金额：
    $0.0万
  • 财政年份：
    --
  • 负责人：
    Deborah Merke
  • 依托单位：
    CLINICAL CENTER
海外基金